A partner in the firm's White Collar Defense & Investigations group, Debra Schreck has significant experience representing clients in complex investigations and litigation matters across a wide range of industries.
A go-to advisor for life sciences clients, Ms. Schreck represents pharmaceutical and medical device companies in connection with criminal and civil investigations by federal and state government agencies, including the US Department of Justice, US Attorneys' Offices and state Attorneys General.
Ms. Schreck defends clients in federal and state litigation, including actions brought under the qui tam provisions of the False Claims Act and involving the Food, Drug & Cosmetic Act, the Anti-Kickback Statute and other healthcare statutes and regulations. She also conducts and counsels clients in connection with large-scale internal investigations and internal training programs.
In addition to her expertise in healthcare, Ms. Schreck leads internal investigations for corporations and institutions related to workplace issues, including allegations of harassment and other misconduct. Ms. Schreck serves on the firm's Recruiting Committee and is active in the firm's mentoring program.
- Eli Lilly and Company in qui tam suit brought by a relator in Eastern District of Texas, alleging kickback claims in connection with nurse education and reimbursement support programs.
- Novartis Pharmaceuticals Corporation and Novartis Corporation in successful defense of a qui tam suit brought in District of Massachusetts by multiple relators, alleging off label and kickback claims in connection with the asthma medication, Xolair®. On a motion to dismiss, obtained dismissal with prejudice of all claims. United States ex rel. Garcia et al. v. Novartis Pharmaceuticals Corporation et al., 06 Civ. 10465 (WGY). Dismissal with prejudice of all federal claims was affirmed by the First Circuit. United States ex rel. Kelly et al. v. Novartis Pharmaceuticals Corporation et al., 827 F.3d 5 (1st Circuit 2016). Relators then filed suits in multiple state courts under state FCA statutes; those cases were also subsequently dismissed.
- Mallinckrodt Pharmaceuticals, in class action litigation alleging antitrust and marketing claims relating to one of its products.
- Bayer Corporation, Bayer HealthCare Pharmaceuticals and Merck & Co., in federal and state product liability litigation involving two fluoroquinolone antibiotics, Avelox® and Cipro®.
- Canon Business Process Services and General Electric, in data breach class action litigation in the Southern District of New York.
- Major brand name prescription drug manufacturer in qui tam litigation brought in Southern District of New York by government and relator, alleging kickbacks to specialty pharmacies in connection with various medications.
- Medical device manufacturer in multi-district federal investigation involving allegations of off-label promotion and kickbacks.
- Medical device manufacturer in federal investigation involving allegations of kickbacks.
- Pharmaceutical company in internal investigation of alleged violations of FDA regulations.
- Biotech company in internal investigation involving alleged violations of healthcare regulations.
- Pharmaceutical manufacturer in connection with US Congressional inquiry.
- JD, Fordham University School of Law, 2006, magna cum laude, Order of the Coif
- BA, Yeshiva University, 2003, summa cum laude, Valedictorian
- New York
- New Jersey
- US Court of Appeals for the First Circuit
- US District Court, Southern District of New York
- US District Court, Eastern District of New York
- US District Court, District of New Jersey